Dermatology

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

Topical niacinamide stabilizes the skin's outer barrier, reducing water loss and improving moisture levels in the epidermis.

In addition to current treatment regimens, 2 experts discuss how available options can vary between adult and pediatric patients.

In addition to highlighting the difficulties patients face when managing plaque psoriasis and atopic dermatitis, 2 experts describe how pharmacists play a crucial role in treatment.

With a wide array of OTC products, pharmacists can help patients select the right regimen

Treating older patients requires a greater focus on treating their AD without exacerbating their comorbidities.

OTC products can help winter-proof skin and prevent dermatological flare-ups

Berdazimer topical gel, 10.3% (Zelsuvmi; Ligand Pharmaceuticals Inc) has been approved for the treatment of molluscum contagiosum in individuals aged 1 year and older.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Biologics for plaque psoriasis has been associated with an atopic dermatitis phenotype, paradoxical eczema, but the risk factors are not well known.

Acne is one of the most common conditions, with about 50 million Americans dealing with acne annually.

It's key for clinicians to optimize therapy prior to systemic agents.

Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.

Pharmacists should educate patients on proper application of OTC hair loss products and help identify any medications that may be contributing.

The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.

Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.

A supplemental New Drug Application will be submitted for roflumilast cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age.

August's Condition Watch focuses on skin health.

Although SB5 is an effective treatment for plaque psoriasis, it is recommended that patients consider the potential risks and adverse effects.

Results of phase 3 trials could lead to the approval of remibrutinib to provide more effective and controlled treatment of chronic spontaneous urticaria than H1-antihistamines.

Patients on risankizumab also reported greater satisfaction with treatment for moderate plaque psoriasis.

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

This approval makes ritlecitinib, in the 50 mg dosage, the first and only treatment approved by the FDA for adolescents aged 12 years and older with severe alopecia areata.

Acne, atopic dermatitis, rosacea, urticaria, and sunburn present differently and require specific management.